Effects of estradiol, cyproterone acetate, tibolone and raloxifene on uterus and aorta atherosclerosis in oophorectomized cholesterol-fed rabbits

Maturitas

Volumn 45, Issue 1, 2003, Pages 59-66

  Sanjuan A ^a   Castelo Branco, C ^a   Colodron M ^a   Ascaso, C ^a   Vicente, J J ^a   Ordi, J ^a   Casals, E ^a   Mercade I ^a   Escaramis G ^a   Vanrell, J A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cyproterone acetate; Estradiol; Experimental atherosclerosis; Raloxifene; Tibolone

Indexed keywords

CHOLESTEROL; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; ESTRADIOL VALERATE; RALOXIFENE; TIBOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; AUTOPSY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; NONHUMAN; OVARIECTOMY; RABBIT; TISSUE LEVEL; UTERUS; UTERUS WEIGHT;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0038175026     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00086-0     Document Type: Article

References (39)

1. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20:(1):1991;47-63. Nurses Health Study.
2. Effects of estrogen or estrogen/progestogen regimens on heart disease risk factors in postmenopausal women. J. Am. Med. Assoc. 273:1995;199-208.
3. Genazanni A., Benedek-Jaszman L.J., Hart D.M., Andolsek L., Kicovic P.M., Tax L. Org OD 14 and the endometrium. Maturitas. 13:1991;243-251.
4. Cohen F.J., Watts S., Shah A., et al. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet. Gynecol. (US). 95:(1):2000;104-110.
5. Zandberg P., Peters J.L., Demacker P.N., Smit M.J., de Reeder E.G., Meuleman D.G. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arterioscler. Thromb. Vasc. Biol. 18:1998;1844-1854.
6. Tang B., Markiewicz L., Kloosterboer H.J., Gurpide E. Human endometrial 3-beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestogenic activity ratios of a steroidal drug (Org OD 14). J. Steroid Biochem. Mol. Biol. 45:1993;345-351.
7. Bjarnason N.H., Haarbo J., Byrjalsen I., et al. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation. 96:1997;1964-1969.
8. Bjarnason N.H., Haarbo J., Byrjalsen I., et al. Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits. Clin. Endocrinol. 52:2000;225-233.
9. Clarkson T.B., Anthony M.S., Jerome C.P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 83:1998;721-726.
10. Sarrel P.M. Ovarian hormones and the circulation. Maturitas. 12:1990;287-298.
11. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. New Engl. J. Med. 340:(23):1999;1801-1811.
12. Quéreux C., Abramovici Y., Bohec M., Crépin G., Elia D., Janaud A., Leclère J., Nahamanovici C., Ribot C., Rozenbaum H. Ménopause et facteurs de risque cardiovasculaire: effects de Climene® sur le poids, la pression artérielle et les paramètres lipidiques. Reprod. Hum. Horm. VII:(8):1994;383-388.
13. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. J. Am. Med. Assoc. 280:1998;605-613.
14. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., Furberg C.D., Kowalchuk G.J., Stuckey T.D., Rogers W.J., Givens D.H., Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. New Engl. J. Med. 343:2000;522-529.
15. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., Hsia J., Hulley S., Herd A., Khan S., Kristin Newby L., Waters D., Vittinghoff E., Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy. J. Am. Med. Assoc. 288:2002;49-57.
16. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the WHI randomized controlled trial. J. Am. Med. Assoc. 288:2002;321-333.
17. Folch J., Lees M., Stanley G.H.S. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226:1957;497-509.
18. Zandberg P., Peters J.L.M., Demacker P.N.M., Reeder E.G., Smit M.J., Meuleman D.G. Comparison of the antiatherosclerotic effect of tibolone with that of estradiol and ethinyl estradiol in cholesterol-fed ovariectomized rabbits. Menopause. 8:(2):2001;96-105.
19. Blümel J.E., Castelo-Branco C., González P. Moyano C., Iturriaga M., Videla L., Sanjuán A., Cano A. Transdermal estrogens do not appear to modify the extension of lesional areas of aortic atherosclerosis in oophorectomized rabbits on a cholesterol-rich diet. Atherosclerosis. 148:2000;303-308.
20. Haines C.J., James A.E., Panesar N.S., Ngai T.J., Sahota D.S., Jones R.L., Chang A.M.Z. The effect of percutaneous oestradiol on atheroma formation in ovariectomized choleterol-fed rabbits. Atherosclerosis. 143:1999;369-375.
21. Haarbo J., Leth-Espensen P., Stender S., Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J. Clin. Invest. 87:1991;1274-1277.
22. Hayashi T., Jayachandran M., Sumi D., Thakur N.K., Esaki T., Muto E., Kano H., Asai Y., Iguchi A. Physiological concentration of 17β-estradiol retards the progression of severe atherosclerosis induced by a high-cholesterol diet plus balloon catheter injury. Role of NO. Arterioscler. Thromb. Vasc. Biol. 20:2000;1613-1621.
23. Hanke H., Hanke S., Bruck B., Brehme U., Gugel N., Finking G., Mück A.O., Schmahl F.W., Hombach V., Haasis R. Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis. 121:1996;129-138.
24. Alexandersen P., Haarbo J., Sandholdt I., Shalmi M., Lawaetz H., Christiansen C. Norethindrone acetate enhances the antiatherogenic effect of 17β-estradiol. Arterioscler. Thromb. Vasc. Biol. 18:1998;902-907.
25. Brehme U., Bruck B., Gugel N., Wehrmann M., Hanke S., Finking G., Schmahl F., Hanke H. Aortic plaque size and endometrial response in cholesterol-fed rabbits treated with estrogen plus continuous or sequential progestin. Arterioscler. Thromb. Vasc. Biol. 19:1999;1930-1933.
26. Sanjuán A, Castelo-Branco C, Vicente JJ, Ascaso C, Ordi J, Casals E, Mercadé I, Escaramís G, Vanrell JA. Cyproterone acetate could counteract the benefits of estradiol valerate in oophorectomized cholesterol-fed rabbits, Menopause, 2002;9:282-287.
27. Felton C.V., Crook D., Davies M.J., Oliver M.F. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler. Thromb. Vasc. Biol. 17:1997;1337-1345.
28. Rekhter M.D., Hicks G.W., Brammer D.W., Work C.W., Kim J.S., Gordon D., Keiser J.A., Ryan M.J. Animal model that mimics atherosclerotic plaque rupture. Circ. Res. 83:1998;705-713.
29. Lee R.T., Libby P. The unstable atheroma. Arterioscler. Thromb. Vasc. Biol. 17:1997;1859-1867.
30. Ridker P.M., Buring J.E., Shih J., Matias M., Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 98:1998;731-733.
31. Walsh B.W., Paul S., Wild R.A., Dean R.A., Tracy R.P., Cox D.A., Anderson P.W. The effects of HRT and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. J. Clin. Endocrinol. Metab. 85:2000;214-218.
32. Figtree G.A., Lu Y., Webb C., Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation. 100:1999;1095-1101.
33. Sulistiyani S.J., Adelman A., Chandrasekaran J., Jayo J., St Clair R.W. Effect of 17 alpha-dihydroequilin sulfate, a conjugated equine estrogen, and etynylestradiol on atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 15:(7):1995;837-846.
34. Bjarnason N.H., Haarbo J., Byrjalsen I., Alexandersen P., Kauffman R.F., Christiansen C. Raloxifene and estrogen reduces progression of advanced atherosclerosis - a study in ovariectomized, cholesterol-fed rabbits. Atherosclerosis. 154:2001;97-102.
35. Clarkson T.B., Anthony M.S., Wagner J.D. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 86:2001;5396-5404.
36. Cline J.M., Register T.C., Clarkson T.B. Comparative effects of tibolone and conjugated equine estrogens with and without medroxyprogesterone acetate on the reproductive tract of female cynomolgus monkeys. Menopause. 9:2002;242-252.
37. Bjarnason N.H., Bjarnason K., Haarbo J., Rosenquist C., Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women: J. Clin. Encocrinol. Metabol. 81:1996;2419-2422.
38. Ettinger B., Black D., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Glüer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., Cummings S.R. en representación de los investigadores del MORE (Multiple outcomes of raloxifene evaluation). Reducción del riesgo de fracturas vertebrales en mujeres posmenopáusicas con osteoporosis tratadas con raloxifeno. Resultados de un ensayo clínico aleatorizado de 3 años de duración. J. Am. Med. Assoc. 282:1999;637-645.
39. Boss S., Huster W.J., Neild J.A., Glant M.D. Effects of raloxifene on the endometrium of postmenopausal women. Am. J. Obstet. Gynecol. 177:1997;1458-1464.